Page 1,573«..1020..1,5721,5731,5741,575..1,5801,590..»

Global Biotechnology Reagents Market to Grow at a CAGR of 10.13 … – Yahoo Finance

Posted: April 25, 2017 at 4:42 am

DUBLIN, Apr. 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Biotechnology Reagents Market 2017-2021" report to their offering.

Research and Markets Logo

The global biotechnology reagents market to grow at a CAGR of 10.13% during the period 2017-2021.

The report, Global Biotechnology Reagents Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Ready-to-use reagents help minimize calculation, dilution, and pipetting errors. They reduce the duration of the diagnostic procedure and prevent contamination of samples. These factors have resulted in the demand for ready-to-use reagents among clinical laboratories and hospitals.

According to the report, the biotechnology industry is spending a huge amount on R&D to innovate new techniques and technologies. The companies are more focused to improve the products, their quality, and standards. The biotech companies are majorly spending on protein synthesis, drug assessment, therapeutics, DNA and RNA analysis, and cell culture applications. Biotechnology reagents are used in all the processes.

Further, the report states that biotechnology instruments are often complex and require sophisticated software for various measurement procedures. To operate the instruments and analyze a sample, the user must have a significant level of training with not only the method and the instrument but also the software required to run the analysis and the collection of data.

Key vendors

Other prominent vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by technology

PART 07: Market segmentation by application

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

PART 14: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/dqbbgf/global

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biotechnology-reagents-market-to-grow-at-a-cagr-of-1013-by-2021---rising-demand-for-ready-to-use-reagents-among-clinical-laboratories--hospitals---research-and-markets-300443626.html

Link:
Global Biotechnology Reagents Market to Grow at a CAGR of 10.13 ... - Yahoo Finance

Posted in Biotechnology | Comments Off on Global Biotechnology Reagents Market to Grow at a CAGR of 10.13 … – Yahoo Finance

NutriBullets SuperFood Boost Featuring Plandai Biotechnology’s … – Marketwired (press release)

Posted: April 25, 2017 at 4:42 am

LONDON, UNITED KINGDOM--(Marketwired - Apr 24, 2017) - Planda Biotechnology, Inc. (OTCQB: PLPL) ("Planda" or "the Company"), producer of the highly bioavailable Phytofare Catechin Complex, today announced that NutriBullet SuperFood Fat Burning Boost featuring Planda's Phytofare Catechin Complex will be available at retail outlets across the United States as early as May 2017.As announced last November, Capital Brands, the makers of NutriBullet SuperFoods, will now be featuring Planda's Phytofare Catechin Complex as the active ingredient in their product, SuperFood Fat Burning Boost.Capital Brands is expected to launch the revised product containing Phytofare with their retailers and on their website (nutriliving.com) as early as next month.

Callum Cottrell-Duffield, Chief Operating Officer for Planda Biotechnology, commented, "We are excited to have Phytofare associated with such a fantastic brand as Nutribullet. Their use of Phytofare as an active ingredient in their reformulation is a clear indication of their commitment to use only the best ingredients to ensure that their customers receive a supremely effective product. It is also testimony to our shareholders that we are indeed on the right track and that our Phytofare ingredients are game changers for the supplement industry."

NutriBullet has formulated specialized, plant-based SuperFood products using a variety of plant proteins,prebiotic and other dietary fibers, proprietary spice blends, and other unique ingredients etc. that can be easily combined into healthy smoothies using their industry-leading nutrient extraction blenders. The company uses all GMO-free ingredients sourced from the world's most reputable farms that undergo extensive testing for purity, effectiveness and flavor.

Planda operates an 8,000-acre estate in Mpumalanga, South Africa, where it grows and processes the green tea used in its Phytofare products. The company uses solar power for on-site housing and organic, sustainable farming practices to ensure the highest quality. Between the farm and factory, the company provides employment for hundreds of local families and, through profit sharing and rental payments, is able to bring economic value to the Zulu community.

About Capital Brands LLC Capital Brands LLC and its subsidiaries create, produce, and sell NutriBullet blenders as well as SuperFood formula mixes and other accessories for their blenders that help give the consumer the best possible health benefits using only the best and most quality ingredients available. The company focuses on nutrient extraction in order to deliver the most nutrients possible from food and other ingredients to increase the health of people everywhere. For more information, please visit https://www.nutribullet.com/."NutriBullet" and "SuperFood Fat Burning Boost" are the registered trademarks of Capbran Holdings, LLC.

About Planda Biotechnology, Inc. Planda Biotechnology, Inc. and its subsidiaries develop highly phyto-available extracts. Planda Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

See the article here:
NutriBullets SuperFood Boost Featuring Plandai Biotechnology's ... - Marketwired (press release)

Posted in Biotechnology | Comments Off on NutriBullets SuperFood Boost Featuring Plandai Biotechnology’s … – Marketwired (press release)

Vetr Inc. Downgrades iShares NASDAQ Biotechnology Index (IBB … – The Cerbat Gem

Posted: April 25, 2017 at 4:42 am


BBNS
Vetr Inc. Downgrades iShares NASDAQ Biotechnology Index (IBB ...
The Cerbat Gem
iShares NASDAQ Biotechnology Index (NASDAQ:IBB) was downgraded by Vetr from a buy rating to a hold rating in a research note issued to investors on ...
iShares NASDAQ Biotechnology Index (IBB) Lifted to Buy at Vetr Inc.Sports Perspectives
iShares NASDAQ Biotechnology Index (IBB) Earning Favorable ...BBNS

all 4 news articles »

Go here to read the rest:
Vetr Inc. Downgrades iShares NASDAQ Biotechnology Index (IBB ... - The Cerbat Gem

Posted in Biotechnology | Comments Off on Vetr Inc. Downgrades iShares NASDAQ Biotechnology Index (IBB … – The Cerbat Gem

Why so many biotechnology start-ups, like Theranos, fail | Genetic … – Genetic Literacy Project

Posted: April 25, 2017 at 4:42 am

Two years after the $9 billion start-up unicorn Theranos crumbled, Silicon Valley still appears to be struggling to learn its lesson when it comes to health and medical start-ups. Improbable-sounding companies continue to turn up with tens of millions of dollars in funding, no published research to back them up, and nothing but criticism from scientists.

Venture-capital firms insist that the standard that needs to be met for investment is much higher for medical start-ups, which must prove that their technology works with data, not just a pitch. And yet somehow, when these start-ups finally surface to public consciousness, they dont appear to pass even the most basic smell test with literally any experienced researcher in the field.

There is a pervasive sense in Silicon Valley, bolstered by ten years of world-conquering success, that any sufficiently intelligent, sufficiently driven person can will what they want.

But the move fast and break things mantra that has helped Silicon Valley disrupt countless industries over the last two decades is more dangerous when applied to medical scienceThe things being broken by health start-ups are laws of science and ironclad guidelines for research. When a health start-up moves fast and breaks things, it can directly result in the death, dismemberment, and injury of real people.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Why Silicon Valley Keeps Getting Biotechnology Wrong

For more background on the Genetic Literacy Project, read GLP on Wikipedia

View post:
Why so many biotechnology start-ups, like Theranos, fail | Genetic ... - Genetic Literacy Project

Posted in Biotechnology | Comments Off on Why so many biotechnology start-ups, like Theranos, fail | Genetic … – Genetic Literacy Project

Life Extension and Insilico Medicine Use AI to Develop Ageless Cell – WholeFoods Magazine

Posted: April 25, 2017 at 4:41 am

Fort Lauderdale, FL Life Extension has partnered with Insilico Medicine to introduce Ageless Cell, the first supplement in its GEROPROTECT line to promote healthy aging by inhibiting cellular senescence.

Cellular senescence is a natural part of the aging process where cells no longer function optimally, affecting organ function, cellular metabolism, and inflammatory response. The accumulation of these senescent cells contributes to the process of aging. The Ageless Cell supplements inhibit the effects of cellular senescence by acting as geroprotectors, or interventions aimed to increase longevity and impede the onset of age-related diseases by targeting and inhibiting senescence-inducing pathways and inhibiting the development of senescent cells.

The partnership with Insilico Medicine allowed researchers to use deep learning algorithms to comb through hundreds of studies and thousands of data points a process that could have taken decades to identify four key anti-aging nutrients: N-Acetyl-L-Cysteine (NAC), myricetin, gamma-tocotrienol, and EGCG. These compounds target pathways that are known to contribute to or protect against the development of senescent cells.

Specifically, NAC upregulates signaling pathways that protect cells against oxidative stress, which promotes cellular senescence. It also reduces pathways that promote inflammation. Myricetin regulates a family of stress-responsive signaling molecules known to regulate aging in many tissues. It also promotes cell differentiation and self-repair. Gamma tocotrienol modulates the mevalonate pathway that controls cholesterol production, cancer promotion, and bone formation. And EGCG regulates the Wnt pathway that determines the fate of developing cells and also prevents sugar-induced damage to tissues, helping to suppress their pro-aging effects.

Clinical aging studies are extremely difficult, if not impossible, to perform at this time. Our collaboration with Insilico Medicine has allowed us to develop geroprotective formulations by using artificial intelligence to study very large data sets, said Andrew G. Swick, Ph.D., senior vice president of product development and scientific affairs for Life Extension.

Scientists found these four nutrients have various complementary and reinforcing properties to influence key anti-aging pathways and combat aging factors by modulating specific biological pathways. By rejuvenating near-senescent cells and encouraging the bodys healthy process for dealing with senescent cells, Ageless Cell turns back the clock at the cellular level, said Michael A. Smith, M.D., senior health scientist for Life Extension. Alex Zhavoronkov, Ph.D., CEO of Insilico Medicine said, Together, these four natural compounds represent the beginning of the future anti-aging cocktails identified using artificial intelligence under expert human supervision.

Originally posted here:
Life Extension and Insilico Medicine Use AI to Develop Ageless Cell - WholeFoods Magazine

Posted in Cell Medicine | Comments Off on Life Extension and Insilico Medicine Use AI to Develop Ageless Cell – WholeFoods Magazine

Scientists step closer to finding cause of multiple sclerosis – Medical News Today

Posted: April 25, 2017 at 4:41 am

As they find out more about the cell biology of multiple sclerosis, scientists are gradually unraveling the mysteries of the disease, although the exact causes are still unclear. Now, a new study continues this progress with a significant discovery about a new cellular mechanism. It suggests that high levels of the protein Rab32 disrupt key communications involving mitochondria. The disruption causes these "cellular batteries" to misbehave, leading to the toxic effects seen in the brain cells of people with multiple sclerosis.

The new study is the work of researchers from the University of Exeter in the United Kingdom and the University of Alberta in Canada. They report their findings in the Journal of Neuroinflammation.

Co-author Paul Eggleton, an immunologist and professor at the University of Exeter Medical School, says that multiple sclerosis can have a "devastating impact on people's lives," and yet, unfortunately, the present situation is that "all medicine can offer is treatment and therapy for the symptoms."

Multiple sclerosis (MS) is a disease in which the immune system mistakenly attacks tissue of the central nervous system - which comprises the brain, spinal cord, and optic nerve.

As the disease progresses, it destroys more and more of the fatty myelin sheath that insulates and protects the nerve fibers that send electrical messages in the central nervous system.

This destruction can lead to brain damage, vision impairment, pain, altered sensation, extreme fatigue, problems with movement, and other symptoms.

As research into the cause of MS progresses, scientists are becoming increasingly interested in the role of mitochondria - the tiny components inside cells that produce units of energy for powering the cell.

Fast facts about MS

Learn more about MS

In earlier work, the team behind the new study was the first to provide an explanation for the role of defective mitochondria in MS through clinical and laboratory experiments.

In their new investigation, the researchers study a protein called Rab32, which is known to be involved in certain mitochondrial processes.

They found that levels of Rab32 are much higher in the brains of people with MS and hardly detectable in brains of people without the disease.

They also discovered that the presence of Rab32 coincides with disruption to a communication system that causes mitochondria to malfunction, causing toxic effects in the brain cells of people with MS.

The disruption is caused by a cell compartment called the endoplasmic reticulum (ER) being too close to the mitochondria.

The ER produces, processes, and transports many compounds that are used inside and outside the cell.

The researchers note that one of the functions of the ER is to store calcium, and if the distance between the ER and mitochondria is too short, it disrupts the communication between the mitochondria and the calcium supply.

Calcium uptake into mitochondria is already known to be critical to cell functioning.

Although they did not discover what causes Rab32 levels to increase, the team believes that the problem may lie in a defect in the base of the ER.

The study could help scientists to find ways to use Rab32 as a treatment target, as well as look for other proteins that may cause similar disruptions, note the authors.

"Our exciting new findings have uncovered a new avenue for researchers to explore. It is a critical step, and in time, we hope it might lead to effective new treatments for MS."

Prof. Paul Eggleton

Learn how a new immunotherapy reversed paralysis in mouse models of MS.

Read this article:
Scientists step closer to finding cause of multiple sclerosis - Medical News Today

Posted in Cell Medicine | Comments Off on Scientists step closer to finding cause of multiple sclerosis – Medical News Today

Experimental Stem Cell Therapy Could Treat Damaged Knee Cartilage – BU News Service

Posted: April 25, 2017 at 4:41 am

Skiing in Aspen, Sean Fair mistimed a landing and felt a shooting pain in his right knee as he crumpled into the snow. He had to slide down the steep slope on his left ski. The doctor revealed that Fairs agony originated from a quarter-sized hole in the cartilage of his knee.

For an active person like Fair, traditional surgery options, like a total knee replacement, restrict motion and are less than ideal. Advances in experimental cartilage repair stem cell treatments, however, now offer new opportunities for young patients to preserve mobility, that defining value of youth.

Fair played football, among other sports, in high school. He played tennis in college and continued to play until he had his ski incident at the age of 31.

All of a sudden, not being able to do anything, I felt 80, he said. All my friends would play tennis together but I would have to sit back and watch.

Sean Fair was diagnosed with OCD, or osteochondritis dissecans. This condition typically develops in teenagers but doesnt usually present symptoms until adulthood when the joint experiences some form of trauma. OCD lesions involve holes, cracks, or loose articular cartilage in a joint.

Fair met with Dr. Andreas Gomoll, an orthopedic surgeon at the Brigham and Womens Hospital in Boston. They discussed knee replacement surgery, microfracture surgery and the possibility of using healthy cartilage from a cadaver donor.

Knee replacement surgery for patients as young as Fair often results with low satisfaction. People who receive the standard metal and plastic knee replacement are functionally limited and face unexpected physical challenges when it comes to activities more intense than a walk. Microfracture surgery would be better, but Fairs injury was too large for that to be practical. Fair and Gomoll decided to wait for a cadaver donor. While waiting, however, Fair joined a clinical trial to test a new approach that would fill the gap in his cartilage with stem cells.

Stem cells can be thought of as undecided cells. Theyre mostly present in embryos and neonates, but they are also found in adults as well. Given the correct environment, and depending on the type of stem cell, they can become more specific cells, like muscle cells or cartilage-forming cells. In Fairs case, Gomoll used donated umbilical cord stem cells from healthy babies delivered in the US. Umbilical cord stem cells are useful because they are able to morph into cartilage-forming cells, they dont require the destruction of an embryo and they have immunosuppressive properties that wouldnt cause Fairs body to reject them.

Anatomical representation of the human knee.

The procedure looked simple. Gomoll made a vertical incision in Fairs kneecap, cutting through the skin and the yellow fat to expose the white cartilage. Gomoll used stainless steel tools to clamp open the incision, while he used a metal ring spanner to scrape the edges of the cartilage pothole. (Picture using a spoon to carve a hole in a large eraser.) Next, the surgeon drilled seven coffee stirrer-sized holes into the bone at the bottom of the quarter-sized pothole. He injected the clear stem cell gel into each coffee stirrer-sized hole and then filled the quarter-sized hole up to its edges with the rest of the stem cell gel. Gomoll smoothed down the stem cell gel like icing on a cake. Then he sutured the wound closed.

Fair wasnt quick to start walking right after the procedure. His knee needed to heal and then he would have to follow a strict rehabilitation process of weekly physical therapy sessions.

Months after his surgery, the stem cells in Fairs knee developed into chondrocytes, cells that secrete a matrix of cartilage, and sealed the pothole in Fairs knee. As of now, Fair is thankful for his treatment. His right knee has healed, but hes still not at 100 percent.

My other knee unfortunately, because of all the issues the [right knee] had, also needs reconstruction, Fair said. Ive got to be careful when I carry my two-and-half-yearold down the steps. Functionally I can walk. I can chase him. I can outrun him, still. Other than that, its not a lot of peripheral movement I can do yet.

According to Gomoll, about 15 other Americans have received the same experimental treatment as Fair. Before this therapy can be offered at any hospital in the US, the clinical trial must obtain FDA approval after proving its efficacy with a larger, more randomized sample of patients. But Gomoll doesnt seem too worried. He says hundreds of patients in South Korea have already undergone the same procedure. Getting there will take some time and money; running comprehensive trials is expensive. Once the procedure is approved, Gomoll imagines thousands of cartilage damaged patients like Fair would potentially be treated with stem cells in the United States.

See the original post here:
Experimental Stem Cell Therapy Could Treat Damaged Knee Cartilage - BU News Service

Posted in Cell Therapy | Comments Off on Experimental Stem Cell Therapy Could Treat Damaged Knee Cartilage – BU News Service

Global Stem Cell Therapy Market – Analysis, Technologies and … – Yahoo Finance

Posted: April 25, 2017 at 4:41 am

DUBLIN, April 24, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Stem Cell Therapy Market 2017-2021" report to their offering.

Research and Markets Logo

The global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

The report, Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is evolution of new destinations in the development of stem cell therapies. Traditionally, the US and European countries are the key destinations for clinical trials for stem cell therapy products. However, the transformation of regulatory landscape in countries such as Japan and South Korea has made these regions as attractive destinations for the development of stem cell therapy products.

According to the report, one of the major drivers for this market is increase in federal funding in stem cell therapy. Research and clinical trials of stem cell therapy require huge investment, which many research institutes and small companies cannot afford. Therefore, many federal organizations provide funding to these institutes and small companies to help their innovative ideas in the development of stem cell therapies. Worldwide, many government organizations have noticed the importance of regenerative medicine, and thus they have allocated funds and grants in that area. For instance, in the US, the NIH and CIRM provide most of the funds.

Key vendors

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Understanding of stem cell therapy

Part 06: Ethical issues and regulatory landscape

Part 07: Key clinical trials

Part 08: Market landscape

Part 09: Market segmentation by therapy

Part 10: Market segmentation by applications

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/gdv8s6/global_stem_cell

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-stem-cell-therapy-market---analysis-technologies-and-forecasts-to-2021---increasing-demand-to-develop-effective-drugs-for-cardiology-and-degenerative-disorders---research-and-markets-300444066.html

Continue reading here:
Global Stem Cell Therapy Market - Analysis, Technologies and ... - Yahoo Finance

Posted in Cell Therapy | Comments Off on Global Stem Cell Therapy Market – Analysis, Technologies and … – Yahoo Finance

Global CAR T Cell Therapy Market & Clinical Trials Insight 2022: 99 … – Yahoo Finance

Posted: April 25, 2017 at 4:41 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "Global CAR T Cell Therapy Market & Clinical Trials Insight 2022" report to their offering.

The report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials.

In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex.

The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients.

Companies Mentioned

Key Topics Covered:

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design

3. Principle of Chimeric Antigen Receptor Design

4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase

8. Global Market Scenario of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy

10. Global CAR T Cell Therapy Market Dynamics

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive Landscap

For more information about this report visit http://www.researchandmarkets.com/research/3h29l7/global_car_t_cell

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424006562/en/

Excerpt from:
Global CAR T Cell Therapy Market & Clinical Trials Insight 2022: 99 ... - Yahoo Finance

Posted in Cell Therapy | Comments Off on Global CAR T Cell Therapy Market & Clinical Trials Insight 2022: 99 … – Yahoo Finance

HemaCare Will Attend International Society of Cell Therapy in London – Yahoo Finance

Posted: April 25, 2017 at 4:41 am

LOS ANGELES--(BUSINESS WIRE)--

HemaCare Corporation (HEMA), a leader in cell and tissue collection, processing and cell therapy solutions, will be exhibiting at the annual meeting of the International Society of Cell Therapy (ISCT) in London, UK, May 3-6, 2017. This year marks the 25th anniversary of the ISCT, a global society that unites clinicians, researchers, regulators, technologists and industry partners with a shared vision to translate cellular therapy into clinical practice. HemaCare will meet with its customers and European distributors at the conference and showcase its growing portfolio for cell therapy developers around the world.

Attending this meeting enables us to capture the latest developments in cell therapy and better serve our customer needs, said Pete van der Wal, Chief Executive Officer for HemaCare.The field of cell therapy is rapidly evolving. Our products and services are embedded in some of the most critical phases of translational research, enabling scientists to work with high quality human cells from our well-characterized donor pool.

The conference is being held at ExCel London Conference Center. Look for us there, or view our products and services at http://www.hemacare.com.

About HemaCare

HemaCare specializes in the customization of human-derived biological products and services for customers research and cell therapy protocols. HemaCares network of FDA-registered, GMP/GTP-compliant collection centers ensures donor material is available for fresh shipment to customers, as well as for internal use within HemaCares isolation laboratory. In this laboratory, human biological material such as peripheral blood, bone marrow, and cord blood from donor and patient subjects is isolated into various primary cell types for distribution to customers in fresh and frozen formats. HemaCare's extensive registry of well-characterized repeat donors provides consistent primary human cells and biological products for advanced biomedical research and cellular therapy process development.

For 39 years, HemaCare has provided human-derived primary blood cells and tissues for biomedical research, supported cell therapy clinical trials and commercialization with apheresis collections, and provided a wide range of consulting services. HemaCare directly supports benchtop immunology and oncology research, compound screening for drug discovery, and assay development and qualification, as well as enables customers to advance both autologous and allogeneic cellular therapies. For more information, please visit http://www.hemacare.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424005274/en/

Visit link:
HemaCare Will Attend International Society of Cell Therapy in London - Yahoo Finance

Posted in Cell Therapy | Comments Off on HemaCare Will Attend International Society of Cell Therapy in London – Yahoo Finance

Page 1,573«..1020..1,5721,5731,5741,575..1,5801,590..»